Nektar Therapeutics (NKTR) Rating Reiterated by Jefferies Group LLC
Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research report issued on Friday. They presently have a $23.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target suggests a potential upside of 24.86% from the company’s current price.
NKTR has been the subject of several other research reports. Roth Capital set a $33.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Aegis reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, May 10th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Evercore ISI began coverage on shares of Nektar Therapeutics in a report on Thursday. They issued an “in-line” rating and a $20.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Nektar Therapeutics currently has an average rating of “Buy” and an average target price of $26.10.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 0.98% during trading on Friday, hitting $18.24. 527,999 shares of the stock were exchanged. The stock has a 50-day moving average of $20.53 and a 200 day moving average of $18.52. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88. The stock’s market cap is $2.85 billion.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The company had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS. Equities analysts predict that Nektar Therapeutics will post ($0.94) earnings per share for the current fiscal year.
In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 8,389 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $21.04, for a total value of $176,504.56. Following the sale, the senior vice president now directly owns 51,961 shares in the company, valued at $1,093,259.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roy A. Whitfield purchased 35,000 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was acquired at an average price of $17.95 per share, for a total transaction of $628,250.00. Following the completion of the transaction, the director now owns 133,000 shares of the company’s stock, valued at approximately $2,387,350. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 138,389 shares of company stock worth $2,908,403. 6.10% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the company. Teachers Advisors LLC boosted its stake in shares of Nektar Therapeutics by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 325,456 shares of the biopharmaceutical company’s stock valued at $3,993,000 after buying an additional 47,492 shares during the period. Bank of Montreal Can boosted its stake in shares of Nektar Therapeutics by 21.8% in the first quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 1,464 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Nektar Therapeutics by 2.1% in the first quarter. Louisiana State Employees Retirement System now owns 62,700 shares of the biopharmaceutical company’s stock valued at $1,472,000 after buying an additional 1,300 shares during the period. Everence Capital Management Inc. acquired a new stake in shares of Nektar Therapeutics during the first quarter valued at approximately $238,000. Finally, State of Alaska Department of Revenue boosted its stake in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 460 shares during the period. Hedge funds and other institutional investors own 93.02% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.